Home > Boards > US OTC > Medical - Drugs > Innovation Pharmaceuticals Inc. (IPIX)

The conclusions are slightly different:

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
ZROYPU Member Profile
 
Followed By 2
Posts 264
Boards Moderated 0
Alias Born 11/10/17
160x600 placeholder
Quarterly Report (10-q) Edgar (US Regulatory) - 11/13/2019 9:24:21 AM
Notice of Effectiveness (effect) Edgar (US Regulatory) - 10/22/2019 6:01:03 AM
Post-effective Amendment to Registration Statement (pos Am) Edgar (US Regulatory) - 10/17/2019 5:24:36 PM
Annual Report (10-k) Edgar (US Regulatory) - 9/30/2019 4:38:42 PM
Post-effective Amendment to Registration Statement (pos Am) Edgar (US Regulatory) - 9/20/2019 4:36:18 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/20/2019 4:34:50 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 9/6/2019 4:52:17 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 9/6/2019 4:51:57 PM
Proxy Statement (definitive) (def 14a) Edgar (US Regulatory) - 8/13/2019 4:11:11 PM
Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a) Edgar (US Regulatory) - 8/2/2019 4:29:30 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 7/22/2019 9:30:41 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/16/2019 10:16:34 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 5/10/2019 5:19:36 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/10/2019 7:33:24 AM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 5/10/2019 7:32:13 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 2/8/2019 4:05:27 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 1/31/2019 4:18:06 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 1/31/2019 4:17:16 PM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 1/22/2019 12:08:16 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 1/7/2019 4:32:21 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 12/18/2018 5:02:33 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 12/17/2018 7:07:54 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 12/17/2018 7:02:14 AM
ZROYPU   Monday, 10/21/19 06:03:32 AM
Re: ZROYPU post# 274949
Post # of 277827 
The conclusions are slightly different:

2017 - Our results suggest Kevetrin is a promising new drug in AML patients treatment, both in wild type and, even more, in TP53 mutated tumors, through different molecular mechanisms, giving more therapeutic alternatives in the treatment of this disease.

https://library.ehaweb.org/eha/2017/22nd/180680/roberta.napolitano.kevetrin.preclinical.study.of.a.new.compound.in.acute.html

2019 - Our results show kevetrin alters several key genes and cellular metabolism. Along with cellular data, this study could provide a rationale for an experimental trial in AML patients, especially those carrying TP53 mutation who actually have very few therapeutic options.

https://library.ehaweb.org/eha/2019/24th/267712/roberta.napolitano.kevetrin.dampens.myc.expression.and.cellular.metabolism.in.html?f=listing%3D3%2Abrowseby%3D8%2Asortby%3D1%2Amedia%3D1

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist